FindTrial
Sign In

A prospective observational study of the efficacy and safety of CPT-11 based regimens for UGT1A1 genotype guided patients with metastatic colorectal cancer

A prospective observational study of the efficacy and safety of CPT-11 based regimens for UGT1A1 genotype guided patients with metastatic colorectal cancer

Status
Unknown
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1080220913
Enrollment
2000
Registered
2009-11-10
Start date
2009-11-10
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic colorectal cancer (adenocarcinoma)

Interventions

investigational material(s) Generic name etc : Irinotecan hydrochloride INN of investigational material : Therapeutic category code : 424 Antineoplastic preparations extracted from plants Dosage and

Sponsors

DAIICHI SANKYO COMPANY, LIMITED
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Metastatic colorectal cancer (adenocarcinoma) 2. Patients to receiving FOLFIRI, CPT-11+S-1 and CPT-11 alone therapy (with or without molecular targeted agents) Age requirement none

Exclusion criteria

Exclusion criteria: 1. Contraindications of CPT-11 2. ECOG PS 3-4 3. Patients to receiving CPT-11 as adjuvant chemotherapy 4. History of a pelvic irradiation

Design outcomes

Primary

MeasureTime frame
Progression free survival None—

Secondary

MeasureTime frame
Overall survival, Time to treatment failure, response rate, disease control rate and safety None—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026